BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 11, Pages 2562
Publisher
MDPI AG
Online
2021-05-24
DOI
10.3390/cancers13112562
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
- (2021) Jeffrey A. How et al. Cancers
- Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
- (2020) Hisamitsu Takaya et al. Scientific Reports
- Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits
- (2019) Sushmita Gordhandas et al. GYNECOLOGIC ONCOLOGY
- Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives
- (2019) Stefania Gori et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)
- (2019) Takayuki Enomoto et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls
- (2018) Ang Li et al. GYNECOLOGIC ONCOLOGY
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis
- (2018) C. Marchetti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee
- (2017) Shogo Shigeta et al. Journal of Gynecologic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer
- (2017) Akira Hirasawa et al. Oncotarget
- BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
- (2016) M. Moschetta et al. ANNALS OF ONCOLOGY
- Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening†
- (2016) S. Paluch-Shimon et al. ANNALS OF ONCOLOGY
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations
- (2016) Catherine A. Shu et al. JAMA Oncology
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- BRCA1andBRCA2mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer
- (2015) Ikuko Sakamoto et al. CANCER
- Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study
- (2015) Yakir Segev et al. Familial Cancer
- Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions
- (2015) Johnathan M. Lancaster et al. GYNECOLOGIC ONCOLOGY
- Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction
- (2015) B. A. M. Heemskerk-Gerritsen et al. JNCI-Journal of the National Cancer Institute
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction
- (2015) B. A. M. Heemskerk-Gerritsen et al. JNCI-Journal of the National Cancer Institute
- Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers
- (2015) Janice S. Kwon et al. OBSTETRICS AND GYNECOLOGY
- Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers
- (2014) Laura L. Holman et al. GYNECOLOGIC ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
- (2014) Claudia Marchetti et al. BMC Womens Health
- Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube
- (2013) J. Sehouli et al. ANNALS OF ONCOLOGY
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study
- (2013) Yakir Segev et al. GYNECOLOGIC ONCOLOGY
- The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
- (2012) Mike De Vos et al. BIOCHEMICAL PHARMACOLOGY
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- SEOM clinical guidelines for hereditary cancer
- (2011) Begoña Graña et al. Clinical & Translational Oncology
- Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
- (2010) Christopher G. Przybycin et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
- (2010) Susan M. Domchek JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
- (2009) T. R. Rebbeck et al. JNCI-Journal of the National Cancer Institute
- BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark
- (2008) M. Soegaard et al. CLINICAL CANCER RESEARCH
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
- (2008) Noah D. Kauff et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search